Array enters US market with Braftovi plus Mektovi in skin cancer

28 June 2018

Colorado, USA-based biotech firm Array BioPharma (Nasdaq: ARRY) has been granted approval from the US regulator to market Braftovi (encorafenib) in combination with Mektovi (binimetinib) for certain metastatic melanoma patients.

Analysts had been confident of approval after the firm released a batch of positive data earlier this year, showing the combo almost doubles survival in BRAF-positive melanoma compared to the Roche (ROG:SIX) therapy Zelboraf (vemurafenib).

Array, which acquired the compounds from Switzerland's Novartis (NOVN: VX), was forced to take on a European development partner in order to fulfil competition requirements in Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK